MYR Pharma

Borgwedel, Germany Founded: 2010 • Age: 16 yrs Acquired By Gilead
Surface peptide fragment for treating Hepatitis B and D infections

About MYR Pharma

MYR Pharma is a Healthcare company based in Borgwedel (Germany) founded in 2010 by Jorn Moller and Alexander Alexandrov, and was acquired by Gilead in December 2020. Surface peptide fragment for treating Hepatitis B and D infections. MYR Pharma has raised $10 million across 1 funding round from investors including Gilead, Maxwell Biotech Venture Fund and High-Tech Gründerfonds. The company has 22 employees. Its focus areas include Life Sciences, Infectious Diseases, Drugs and Viral. Its legal entity is MYR GmbH.

Company details

MYR is focussed on developing drugs for the treatment of chronic hepatitis B and D virus infections. It is developing Myrcludex B, a fragment of the pre-S1 surface peptide claims to inhibit the HBV receptor on the hepatocyte surface and prevents the infection of the healthy cells and viral spreading within the liver. It also targets HDV as it uses HBV envelope to infect liver cells. The candidate has finished phase 2a trials for HBV and a pilot trial for HDV is in progress.

  • Headquarters Borgwedel, Germany
  • Employees 22
  • Founders Jorn Moller, Alexander Alexandrov
  • Stage Acquired
  • Sectors
    Healthcare
  • Website myr-pharma.com
  • Social LinkedIn
  • Acquired by Gilead (Dec 2020)
  • Legal Name Myr Gmbh
Operational Areas
Key Metrics
  • Total Equity Funding
    $10M (USD)

    in 1 rounds

  • Latest Funding Round
    $10M (USD), Series A

    Mar 2012

  • Investors
    Gilead

    & 2 more

  • Employee Count
    22
  • Acquired by
    Gilead

    (Dec 2020)

Funding Insights of MYR Pharma

MYR Pharma has successfully raised a total of $10M through 1 strategic funding round. The most recent funding activity was a Series A round of $10 million completed in March 2012. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding $10M
  • Total Rounds 1
  • Last Round Series A — $10M
  • First Round $10M

    (Mar 2012)

  • Investors Count 2

All 1 funding rounds of MYR Pharma with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.

DateAmountTransaction NameValuationLead InvestorsInvestors
Mar 2012$10MSeries A–Maxwell Biotech Venture Fund, HTGF
–
Valuation history

3 investors in total: 3 institutional.

Investors in MYR Pharma

MYR Pharma has secured backing from 3 investors, including institutional and venture fund investors. Prominent investors backing the company include Gilead, Maxwell Biotech Venture Fund and High-Tech Gründerfonds.

All
Venture Fund
Institutional
InvestorDescriptionFounded YearDomainLocation
Early-stage investments are made in high-tech startups by HTGF.
htgf.deBonn, Germany
maxwellbiotech.com
Developer of medicines to treat HIV/AIDS, liver diseases, cancer & others
1987gilead.comFoster City, United States
Premium access

Investor details for MYR Pharma

The complete investor list, round-by-round participation and investor portfolios require an active premium plan.

  • Complete investor list
  • Round participation
  • Investor portfolios
  • Co-investor network

Verified entity values are shown only after access is granted.

People of MYR Pharma

6 people are tracked at MYR Pharma (6 in leadership); the tracked headcount is 22.

NameRoleGroup
Jorn Moller
Co-FounderLeadership
Alexander Alexandrov
Co-FounderLeadership
Norbert Dinauer
COOLeadership
Florian Vogel
Chief Commercial OfficerLeadership
Thomas Christély
CFOLeadership
Dmitry Popov
CEOLeadership
Premium access

Complete people profiles for MYR Pharma

Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.

  • Full employee list
  • Team structure
  • Board tenure
  • Professional contacts

Verified entity values are shown only after access is granted.

Timeline of MYR Pharma

3 dated milestones of MYR Pharma across 10 years, from founding to its latest funding, stage changes and deals.

  1. Founded MYR Pharma is founded.
  2. Funding First funding round of $10.0M.
  3. Exit Acquired by Gilead.
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • ✓
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • ✓
    Full access to every database India & global coverage, advanced filters and rich profile details
  • ✓
    Always-on access from your team account Single premium plan for everything you see on the portal

Related news about Myr Pharma

Premium access

Complete news archive for MYR Pharma

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about MYR Pharma

MYR Pharma was founded in 2010 and raised its 1st funding round 2 years after it was founded.

MYR Pharma is headquartered in Borgwedel, Germany. It is registered at Borgwedel, Schleswig-holstein, Germany.

MYR Pharma is a funded company, having raised a total of $10M across 1 funding round to date. The company's 1st funding round was a Series A of $10M, raised on Mar 2012.

MYR Pharma has 22 employees.

MYR is focussed on developing drugs for the treatment of chronic hepatitis B and D virus infections. It is developing Myrcludex B, a fragment of the pre-S1 surface peptide claims to inhibit the HBV receptor on the hepatocyte surface and prevents the infection of the healthy cells and viral spreading within the liver. It also targets HDV as it uses HBV envelope to infect liver cells. The candidate has finished phase 2a trials for HBV and a pilot trial for HDV is in progress.

MYR Pharma has 3 investors. Key investors include Gilead, Maxwell Biotech Venture Fund, and High-Tech Gründerfonds.

MYR Pharma operates through Myr Gmbh.

Yes. MYR Pharma was acquired by Gilead in December 2020.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available